The ubiquitin ligase Ozz decreases the replacement rate of embryonic myosin in myofibrils

Emi Ichimura | Koichi Ojima | Susumu Muroya | Takahiro Suzuki | Ken Kobayashi | Takanori Nishimura

Abstract
Myosin, the most abundant myofibrillar protein in skeletal muscle, functions as a motor protein in muscle contraction. Myosin polymerizes into the thick filaments in the sarcomere where approximately 50% of embryonic myosin (Myh3) are replaced within 3 h (Ojima K, Ichimura E, Yasukawa Y, Wakamatsu J, Nishimura T, Am J Physiol Cell Physiol 309: C669-C679, 2015). The sarcomere structure including the thick filament is maintained by a balance between protein biosynthesis and degradation. However, the involvement of a protein degradation system in the myosin replacement process remains unclear. Here, we show that the muscle-specific ubiquitin ligase Ozz regulates replacement rate of Myh3. To examine the direct effect of Ozz on myosin replacement, eGFP-Myh3 replacement rate was measured in myotubes overexpressing Ozz by fluorescence recovery after photobleaching. Ozz overexpression significantly decreased the replacement rate of eGFP-Myh3 in the myofibrils, whereas it had no effect on other myosin isoforms. It is likely that ectopic Ozz promoted myosin degradation through increment of ubiquitinated myosin, and decreased myosin supply for replacement, thereby reducing myosin replacement rate. Intriguingly, treatment with a proteasome inhibitor MG132 also decreased myosin replacement rate, although MG132 enhanced the accumulation of ubiquitinated myosin in the cytosol where replaceable myosin is pooled, suggesting that ubiquitinated myosin is not replaced by myosin in the myofibril. Collectively, our findings showed that Myh3 replacement rate was reduced in the presence of overexpressed Ozz probably through enhanced ubiquitination and degradation of Myh3 by Ozz.

KEYWORDS
myofibril, myosin, skeletal muscle, thick filament, ubiquitin ligase, ubiquitin–proteasome system

Emi Ichimura and Koichi Ojima contributed equally to this work.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society
INTRODUCTION

Because of its remarkable plasticity, skeletal muscle tissue can modify its volume to adapt to exercise, disease, development, and aging (Lecker et al., 2006; Nury et al., 2007). Skeletal muscle tissue is composed of bundles of myofibers, which contain highly organized structural components named myofibrils. A single myofiber contains approximately 2,000 of myofibrils in untrained adult humans (Placzek & Boyce, 2016). Myofibrillar proteins, of which there are more than 20 types, are organized into repeated minimal contraction units referred to as sarcomeres (Clark et al., 2002; Henderson et al., 2018). Muscle tissue size is determined by the volume of each muscle fiber, which reflects the number of myofibrils. Therefore, muscle hypertrophy and atrophy depend on increase and decrease of the number of myofibrils, respectively, and, muscle volume is modulated by the balance between the synthesis and degradation of myofibrillar proteins.

Myosin, an abundant myofibrillar protein in the skeletal muscle, functions as a motor protein in muscle contraction. Myosin is composed of two heavy chains and four light chains, and polymerizes into filaments under physiological ionic strength conditions (Craig & Woodhead, 2006; Davis, 1988). In myofibrils, approximately 300 myosin molecules form a single thick filament with myosin-associated proteins such as connectin/titin, myomesin, and myosin-binding protein C (MybpC) (Kontrogianni-Konstantopoulos et al., 2009; Labeit & Titins, 1995; Obermann et al., 1997). Each sarcomere contains thick and thin filaments that are arranged in a regular pattern; thin filaments are composed of actin, troponin complex, tropomyosin, and nebulin (Prill & Dawson, 2020). The interaction of myosin in the thick filaments with actin in the thin filaments induces muscle contraction, coupled with ATP hydrolysis by myosin (Walklate et al., 2016).

Skeletal muscle is classified into two categories according to the velocity of muscle contraction, i.e., slow and fast types. This feature is attributed to the expression of myosin heavy chain (Myh) isoforms with different rates of ATPase activity and muscle contraction velocity in each myofiber (Resnicow et al., 2010; Walklate et al., 2016). Slow type muscle fibers express Myh7, whereas fast type myofibers express Myh1, Myh2, and/or Myh4. Although slow and fast types of Myhs are dominantly expressed in adult skeletal muscles, other Myh isoforms such as embryonic (Myh3) and neonatal (Myh8) types are expressed during muscle development. Fast type of Myhs gradually becomes predominant a few days after birth in mice, which causes the down-regulation of Myh3 and Myh8, resulting in Myh isoform shift in myofibrils (Schiaffino et al., 2015).

Proteins are regularly degraded to maintain protein quality and quantity in vivo. One of the main degradation systems in skeletal muscle is the ubiquitin–proteasome system (UPS), which selectively degrades target proteins (Lecker et al., 2006; Passmore & Barford, 2004). In the UPS, ubiquitin (Ub) is activated by the E1 ubiquitin-activating enzymes in an ATP-dependent manner and is transferred to an E2 ubiquitin-conjugating enzyme. The E3 ubiquitin ligase which selectively recognizes substrate proteins recruits the E2, catalyzing the transfer of Ub to a lysine (K) residue of the substrate (Passmore & Barford, 2004). Polyubiquitination on the substrate protein is classified for degradation by the proteasome (Huang & Zhang, 2020).

In striated muscle, muscle ring finger protein 1 (Murf1) and muscle atrophy F-box (MAFbx) are muscle-specific E3s that are up-regulated under conditions of muscle atrophy (Bodine et al., 2001). Murf1 is a member of the Murf family, which ubiquitates multiple myofibrillar proteins containing the slow and fast types of Myh (Cohen et al., 2009; Fielitz et al., 2007). Potential target proteins of MAFbx in sarcomeres include Myh, vimentin, and desmin (Lokiredy et al., 2011, 2012), in addition to its well-known substrates MyoD and eukaryotic translation initiation factor 3 (Lagirand-cantaloube et al., 2008; Tintignac et al., 2005). Neuralized E3 ubiquitin protein ligase 2 (Neurl2) which is referred to as Ozz, another muscle-specific E3, is up-regulated during myotube formation (Campos et al., 2010). Ozz, a member of the suppressor of cytokine signaling family, functions as an E3 in a complex containing Elongin B/C, Rbx1, and Cullin 5 (Kile et al., 2002). Ozz ubiquitinates Myh3 (Campos et al., 2010), and knockdown of Ozz causes defects in myofibril formation (Nastasi et al., 2004). Therefore, Ozz is a critical skeletal muscle E3 at the embryonic stage.

In a previous study, we investigated the myosin replacement rate in myofibrils using fluorescence recovery after photobleaching (FRAP) technique in myotubes expressing enhanced green fluorescence protein (eGFP) tagged Myh3. The half-life of myosin is approximately 5 days as measured by the radioisotope technique in muscle cells (Rubinstein et al., 1976; Zak et al., 1977); however, we found that myosin molecules in myofibrils are replaced more frequently, i.e., approximately 50% of myosin molecules in myofibrils are replaced within 3 h (Ojima et al., 2015). The myosin in myofibrils is replaced by another myosin molecule that is newly synthesized and/or derived from a cytosolic pool of myosin (Ojima et al., 2015, 2017). However, the role of protein degradation system in myosin replacement has not been investigated. In this study, we examined the effect of Ozz overexpression on eGFP-Myh3 replacement rate. The result showed that Ozz up-regulation promoted the ubiquitination and degradation
of myosin, thereby decreasing the rate of embryonic myosin replacement. The present findings underscore the importance of the UPS in myosin replacement in skeletal muscle cells.

2 | MATERIALS AND METHODS

2.1 | Experimental animals

All experiments were performed using primary muscle cells from chick embryos. Experimental animals were cared for as outlined in the guidelines of Hokkaido University and NARO for the care and use of laboratory animals. This study was approved by the two committees.

2.2 | Cell culture and transfection

Skeletal muscle cells were isolated from the pectoral muscles of 11-day-old chick embryos without sex determination as described previously (Ojima et al., 2015). After removing connective tissue under a stereomicroscope, minced muscles were incubated with a 0.025% trypsin solution for 25 min at 37°C. Trypsinization of the muscle slurry was stopped by addition of growth medium [10% (v/v) horse serum (Thermo Fisher Scientific), 10% (v/v) embryo extract, and 1% (v/v) penicillin–streptomycin–glutamine ×100 (Thermo Fisher Scientific) in minimum essential medium (Thermo Fisher Scientific)]. The cell suspension was centrifuged at 600 g for 5 min, and the precipitate was dissolved in 5-ml growth medium and filtered through 100- and 40-µm cell strainers (CORNING). Cells were cultured on an uncoated 60-mm dish at 37°C for 50 min to remove contaminating non-muscle cells. The non-adherent cell fraction containing skeletal muscle cells was seeded at a density of 7500–10,000 cells/cm² on dishes coated with poly-L-Lysine (Sigma-Aldrich) and collagen Type I-A (Nitta Gelatin). One day after seeding, the cells were transfected with expression vectors using Lipofectamine® LTX and Plus reagents (Thermo Fisher Scientific).

The growth medium was replaced by differentiation medium [11% (v/v) horse serum, 3% (v/v) embryo extract, and 1% (v/v) penicillin–streptomycin–glutamine ×100 in minimum essential medium] 1 day after transfection or after reaching 70% cell confluence. The differentiation medium was replaced every 2 days. Once myotubes were formed, 10-µM cytosine arabinoside (Tokyo Chemical Industry) was added to the medium to remove mitotic non-muscle cells. For MG132 treatment, MG132 (Peptide Institute) was added to the differentiation medium at a final concentration of 1 µM for 16 h.

2.3 | cDNA constructs

Mouse cDNAs for Myh1 (85-5913 in NM_030679), Myh3 (45–5868 in NM_001099635), and Myh7 (142-5949 in NM_080728) were cloned into the pEGFP-C1 vector (TAKA B A BIO). Mouse cDNA for Neurl2 (Ozz, 157-1014 in NM_001082974) was cloned into the pmCherry vector (TAKA B A BIO). The inserted sequences of all constructs were verified with a 3730 DNA Analyzer (Applied Biosystems).

2.4 | Real-time quantitative PCR assay (RT-qPCR)

Total RNA was isolated from differentiated muscle cells using ISOGEN (Nippon Gene) according to the manufacturer’s instructions. The first strand cDNA was synthesized using ReverTra Ace (Toyobo). RT-qPCR was performed with a CFX96 Real-Time PCR Detection System (Bio-Rad) using the QuantiTect SYBR Green PCR System (Qiagen). The primer pairs used in this study are listed in Table 1.

PCR conditions were as follows: 15 min at 95°C, 45 cycles of 15 s at 94°C, 30 sec at 65°C and 30 s at 72°C. GAPDH was used as an internal control.

2.5 | Fluorescence recovery after photobleaching (FRAP) assay

The FRAP assay was performed using transfected myotubes cultured on glass-based dishes (IWAKI, Shizuoka, Japan) with a Leica TCS SP5 (Leica microsystem) as described previously (Ojima et al., 2015). Cells were incubated at 37°C and 5% CO₂ on the microscope incubation system (TakaiHit) during FRAP experiments. The emission wavelengths of eGFP and mCherry were 488 and 543 nm, respectively, and band-pass filters were 500–540 nm and 600–700 nm, respectively. A 100 µm² region of interest (ROI) was selected in each cell. The fluorescence of ROIs was bleached by exposure to an argon laser at a strength of 100% for 30 s. Fluorescence recovery was monitored every hour after photobleaching. The fluorescence intensity of the ROI was quantified and normalized to that of the non-bleaching area at each time point. The normalized fluorescence intensities were used in the following exponential curve fitting formula calculated by ImageJ 1.52a (National Institutes of Health) software:

\[ FI = M_f \times (1 - e^{-b \times t}) + c, \]

where FI is the normalized fluorescence intensity, Mf is the mobile fraction, b is the speed constant, c is the fluorescence intensity after bleaching, and t is the elapsed time after bleaching.
Mf was used for the maximum value of fluorescence intensity change. The 5% recovery time (5% Rt) indicated the time required to reach a fluorescence recovery of 5% of pre-bleaching intensity, and was calculated from In[Mf/(Mf-0.05)]/b. The 5% Rt was used for the parameter of speed for fluorescence recovery at the initial rise time.

2.6 Immunoprecipitation and western blotting

Immunoprecipitation samples were obtained from cells co-transfected with eGFP-Myh3 and mCherry-Ozz. To increase the amount of ubiquitinated proteins, myotubes were treated with 1 µM MG132, a proteasome inhibitor, for 16 h. Immunoprecipitation was conducted under denature condition (Koyama et al., 2008). The cytosolic fraction was obtained by treating cells with modified chemical skinned-fiber buffer [10 mM Tris-HCl pH 7.5, 150 mM CsCl, 1 mM EDTA Cs, 0.5% (v/v) Triton X-100, 0.1% (w/v) sodium dodecyl sulfate, 2% protease inhibitor cocktail (Sigma-Aldrich), 0.06 mM leupeptin (Peptide Institute), 0.7 µM calpastatin (Takara Bio), and 25 µM MG132 (Peptide Institute)] for 30 min at 4°C. To remove cellular debris, the soluble fraction was centrifuged at 1500 g for 5 min. The supernatant was further centrifuged at 20,000 g for 20 min to obtain the cytosolic fraction. Precipitation fraction was prepared from myotubes after chemical skinned-fiber buffer treatment. Skinned myotubes were collected in high-salt lysis buffer [10 mM Tris-HCl pH 7.6, 0.6 M CsCl, 1 mM EDTA Cs, 0.5% (v/v) Triton X-100, 0.1% (w/v) sodium dodecyl sulfate, 2% protease inhibitor cocktail (Sigma-Aldrich), 0.06 mM Leupeptin, 0.7 µM Calpastatin, 25 µM MG132]. Samples were homogenized with 27-G syringes and rotated at 4°C for 15 min to solubilize myosin. After centrifugation at 20,000 g for 20 min, the high-salt soluble fraction was used as a myofibril fraction. The cytosolic and the myofibril samples were pre-treated with agarose-conjugated protein G (Santa Cruz Biotechnology) for 1 h to remove nonspecific proteins bound to the agarose beads. The supernatants were then reacted with anti-myosin antibody (1:100; clone MF20, R&D Systems, Minneapolis, MN, USA) followed by protein-G-conjugated agarose beads at 4°C for 1 h. The beads were washed with modified chemical skinned fiber buffer five times and then boiled with Laemmli sample buffer [125 mM Tris-HCl pH 6.8, 20% (v/v) glycerol, 4% (w/v) SDS, 0.02% (w/v) bromophenol blue, and 0.2 M dithiothreitol] at 95°C for 5 min.

2.7 Western blotting

Samples were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by transfer to PVDF membranes (Merck). Membranes were blocked with 0.5% (w/v) bovine serum albumin (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan) at room temperature for 30 min and then incubated at 4°C for 16 h with one of the following antibodies: mouse anti-myosin heavy chain (1:1000; clone MF20, R&D Systems), mouse anti-ubiquitin (1:1,000; clone VB2880, VIVA Bioscience), and mouse anti-mRFP (1:1,000; clone mix of I9G and 3B5, MBL). Following incubation with peroxidase-conjugated mouse secondary antibodies (NICHIREI BIOSCIENCES), bands were visualized with the POD immunostain kit.
(FUJIFILM Wako Pure Chemical Corporation) or ECL Western Blotting Detection Reagents (GE HealthCare). For band quantification, signal intensities of bands were analyzed by ImageJ 1.52a (National Institutes of Health). As T. Nastasi, et al (Nastasi et al., 2004) described previously, the ratios of Ub-Myh band intensity to Myh band intensity were calculated as follows: (the signal intensity of Ub-Myh band/ the lower Ig band) / (the signal intensity of Myh band / the lower Ig band). The ratios were then normalized with values of controls.

2.8 Immunofluorescence staining

Myotubes cultured in 8-well chambers (Thermo Fisher Scientific) were treated with MG132 for 16 h before fixing and washing with 0.5% (v/v) Triton X-100 in PBS. Then, myotubes were blocked with 0.5% (w/v) bovine serum albumin (FUJIFILM Wako Pure Chemical Corporation) at room temperature for 30 min. After blocking, myotubes were reacted with mouse anti-ubiquitin antibody (1:100; clone VU-1, LifeSensors, Malvern, PA, USA) and rabbit anti-pan sarcomeric myosin heavy chain antibody (1:4,000; kindly gifted by Prof. Howard Holtzer, Univ. Penn), followed by incubation with FITC and TRITC secondary antibodies (anti-Rabbit, 611-102-122, Rockland, PA, USA) (anti-mouse, #55527, Cappel, NC, USA). Specimens were mounted with mounting media (Thermo Fisher Scientific) and observed using the Leica TCS SP5 (Leica microsystem).

2.9 Statistics

All data are expressed as the mean ± standard error (SE) with individual datapoints. Control and each trial data were compared using the t-test. Statistical significance was set at p < 0.05. All statistical tests were performed using EZR on R commander ver. 1.40.

3 RESULTS

3.1 Overexpressed Ozz localizes to the cytosol and does not alter the expression levels of eGFP-Myh3 and endogenous Ozz

To explore the involvement of the UPS in myosin replacement, we examined the role of the Myh3-specific E3 ligase Ozz (Campos et al., 2010). First, we tested whether exogenously expressed Ozz localized to specific regions in myotubes. Cultured skeletal muscle cells were transfected with constructs encoding eGFP-Myh3 and mCherry-Ozz. Although exogenously expressed mCherry-Ozz was mainly distributed as puncta between myofibrils, the mCherry-Ozz puncta did not affect the structure of eGFP-positive thick filaments (Figure 1a–f). Figure 1G shows that the molecular weight of exogenously expressed mCherry-Ozz in myotubes. The effect of exogenously overexpressed Ozz on the expression levels of endogenous Ozz and exogenous eGFP-Myh3 was examined by RT-qPCR. The results showed that the mRNA expression levels of endogenous Ozz did not differ significantly between the Ozz overexpressing and the control groups (Figure 1h–i), and eGFP-Myh3 was expressed at comparable levels in the two groups (Figure 1j). Furthermore, we confirmed that Ozz overexpression did not change the expression levels of endogenous Murf family members (Figure 1k–m). These results indicate that exogenously expressed mCherry-Ozz did not alter the expression levels of endogenous Ozz and Murf family, and exogenous eGFP-Myh.

3.2 mCherry-Ozz overexpression decreases the replacement rate of the eGFP-Myh3

To examine effect of Ozz overexpression on eGFP-Myh3 replacement, myotubes co-expressing eGFP-Myh3 and mCherry-Ozz were analyzed using the FRAP assay. Changes in fluorescence intensity at the bleaching area were measured at 1-h intervals after fluorescence bleaching to determine the fluorescence recovery of eGFP-Myh3 in myotubes overexpressing mCherry or mCherry-Ozz (Figure 2a). The eGFP-Myh3 fluorescent recovery rate was lower in myotubes expressing mCherry-Ozz than in control myotubes (Mf 27.8% ±2.1% in Myh3+Ozz vs. 35.6% ±2.6% in Myh3, p = 0.048), although the recovery time of eGFP-Myh3 did not differ significantly from that of the control (5% Rt 0.73 ± 0.12 h in Myh3+Ozz vs. 0.99 ± 0.11 h in Myh3, p = 0.133) (Figure 2b–d). These results indicate that overexpression of Ozz decreased the eGFP-Myh3 replacement rate in myofibrils.

3.3 Ozz does not alter the replacement rate of eGFP-Myh1 and eGFP-Myh7

Because overexpression of Ozz decreased the replacement rate of eGFP-Myh3 (the embryonic myosin isoform), we tested the effects of Ozz on the replacement rates of other myosin isoforms such as Myh1 and Myh7. eGFP-Myh1 and eGFP-Myh7 were localized to the A-bands in myotubes overexpressing mCherry and
mCherry-Ozz (Figure 3a,e). The results of the FRAP assays showed that the replacement rate of eGFP-Myh1 in myotubes co-expressing mCherry-Ozz did not differ significantly from that in control myotubes overexpressing mCherry (Figure 3a–d). Similarly, Ozz overexpression did not decrease the replacement rate of eGFP-Myh7 in myotubes overexpressing mCherry-Ozz (Figure 3e–h). These results indicate that overexpression of Ozz specifically reduced the replacement rate of eGFP-Myh3, whereas it had no effect on eGFP-Myh1 and eGFP-Myh7.

3.4 | Ozz induces myosin ubiquitination in myotubes

Since Ozz functions as a Myh3-specific Ub ligase (Campos et al., 2010), we hypothesized that the Ozz-induced decrease in the myosin replacement rate was caused by the effect of Ozz overexpression on targeting eGFP-Myh3 for degradation. To address this, cultured muscle cells were separated into a cytosolic fraction and a myofibril fraction, and ubiquitinated myosin was detected by immunoprecipitation...
and immunoblotting in each fraction. Cells were treated with MG132 to detect ubiquitinated myosin, because ubiquitin bands scarcely detected without MG132 treatment (Figure 4a,c). In the cytosolic fraction, the relative signal intensity of ubiquitinlated-Myh detected by immunoblotting was significantly higher in muscle cells overexpressing Ozz than in control muscle cells (1.00 ± 0.11 in Myh3, 1.75 ± 0.18 in Myh3+Ozz) (Figure 4a,b). In the myofibril fraction, the signal intensity of ubiquitinlated-Myh had no difference (1.00 ± 0.10 in Myh3, 1.10 ± 0.74 in Myh3+Ozz) (Figure 4c,d). Intriguingly, the band intensities of anti-ubiquitin antibody were scarcely detectable in the myofibril fraction with MG132. These results indicate that overexpression of Ozz increased Myh ubiquitination and probably enhanced UPS-mediated degradation in the cytosol.

### 3.5 Ubiquitinated-Myh is abundant in the cytosolic fraction and is not replaced in the thick filament

The present results indicate that Ozz decreased the Myh3 replacement rate by promoting myosin degradation.
We, therefore, explored the effect of inhibition of protein degradation on myosin replacement. To address this, cultured muscle cells were treated with the proteasome inhibitor MG132, which does not inhibit ubiquitination but does inhibit protein degradation by UPS. MG132 treatment increased the level of ubiquitinated proteins in the cytosolic and myofibril fractions (Figure 5a). To test the effect of inhibition of protein degradation on myosin replacement, myotubes expressing eGFP-Myh3 in the presence or absence of MG132 were analyzed using the FRAP assay. eGFP-Myh3 was detected in the thick filaments of myofibrils in myotubes treated with MG132, indicating that MG132 did not disrupt the myofibrils structure (Figure 5b). FRAP assays indicated that the replacement
rate of eGFP-Myh3 was significantly lower in MG132-treated myotubes than in the control group (Figure 5c–e). These results suggest that ubiquitinated myosin is not frequently replaced in myofibrils in the presence of MG132. Next, we examined the localization of ubiquitin in myotubes treated with or without MG132. Ubiquitin was not detected in the thick filaments, but rather in the cytoplasm in a diffuse pattern or in small puncta. This microscopic observation was consistent with the immunoblot data and indicated that ubiquitinated myosin predominantly localized to the cytoplasm, suggesting that ubiquitinated myosin is not the primary source for myosin substitution in myofibrils (Figure 5f).

4 | DISCUSSION

In this study, overexpression of Ozz decreased the Myh3 replacement rate in myotubes probably through promoting the ubiquitination and degradation of Myh3. MG132 treatment led to the accumulation of ubiquitinated-Myh in the cytosol rather than in the myofibrils of myotubes, suggesting that the myosin in myofibrils was not replaced by ubiquitinated myosin. Myosin in the cytosol is one of the main source for myosin replacement (Ojima et al., 2017). The decrease of replaceable myosin in the cytoplasm of myotubes caused by increased ubiquitination by Ozz and UPS-mediated degradation led to a low myosin replacement rate in myofibrils.

In the present study, Ozz overexpression specifically decreased eGFP-Myh3 replacement rate. Because Myh3 is a substrate of the E3 ligase Ozz (Campos et al., 2010), we hypothesized that Ozz overexpression promoted the ubiquitination and proteasomal degradation of eGFP-Myh3. The increased degradation rate of Myh3 may have limited the supply of Myh3 for myosin substitution, thereby decreasing the eGFP-Myh3 replacement rate. This hypothesis was supported by the results showing that Ozz overexpression increased myosin ubiquitination in the cytosol, and not in the myofibrils (Figure 4). The finding that overexpressed mCherry-Ozz did not localize to the myofibrils suggests that Ozz promotes the degradation of myosin in the soluble cytosolic fraction rather than in the myofibril. This is similar to other E3s such as Murfs (Cohen et al., 2009; Solomon & Goldberg, 1996), which capture myosin in the soluble cytosolic fraction of skeletal muscle cells. In addition, Ozz may target impaired or expendable myosin for degradation in the cytosolic fraction rather than in the myofibrils. It is unlikely that Ozz captures impaired or expendable myosins in the thick filaments because Ozz
interacts with myosin through the assembly competence domain of Myh3 (1873–1901 aar) (Campos et al., 2010), which is essential for the formation of the thick filaments and is concealed in the thick filament (Sohn et al., 1997). Therefore, interaction with Ozz may interfere with the incorporation of the Myh–Ozz complex into the thick filaments, leading to a decrease in the myosin replacement rate in myotubes overexpressing Ozz.

Another possible explanation for the reduction in Myh3 replacement rate in myotubes overexpressing Ozz and myotubes treated with MG132 is that ubiquitination of Myh3 changes its biochemical properties. Ubiquitination is a post-translational modification (Passmore & Barford, 2004) that functions not only as a tag for degradation, but also as a modification factor for protein solubility (Dao et al., 2018; Sharkey et al., 2018). Biochemical studies demonstrated that in the presence of MG132, ubiquitinated myosin accumulated in the cytosol rather than in myofibrils. Furthermore, immunofluorescence studies showed that ubiquitin did not co-localize with myosin in the thick filaments but was instead distributed diffusely in the cytosol (Figure 5f). The modification of myosin with ubiquitin may increase its solubility to prevent the formation of aggregates, which form under physiological ionic conditions (Davis, 1988). Although MG132-treated myotubes contained ubiquitinated myosin in the cytosol, the myosin replacement rate was slow. Thus, it is likely that ubiquitinated myosin in the cytosol is not replaceable in the thick filaments. Moreover, ubiquitinated myosin scarcely accumulated in the absence of MG132 in both the

**Figure 5** Fluorescence recovery of eGFP-Myh3 in myotubes treated with MG132. (a) Ubiquitinated proteins were detected by western blotting. Samples were obtained from muscle cells treated with or without MG132. (b) Representative FRAP images of in myotubes expressing eGFP-Myh3 in the presence of DMSO (control) or MG132. Images were obtained at 1-h intervals after photobleaching. Bleached areas are indicated by yellow rectangles. (c) Normalized fluorescence intensities of eGFP-Myh3 were obtained from DMSO (control) or MG132-treated myotubes. (d and e) Mobile fractions and 5% fluorescence recovery times were calculated. Values represent the mean ± SE. n = 10 for each group. (f) Myotubes treated with or without MG132 were stained with anti-myosin antibody (green) and anti-ubiquitin antibody (red). Nuclei were visualized with DAPI. Bars, 10 µm.
cytosolic and myofibril fraction, suggesting that ubiquitinated myosin is immediately disassembled (Figure 4a,c). The increase in myosin solubility caused by ubiquitination may improve the degradation efficiency by suppressing myosin insertion into myofibrils. Taken together, these observations indicate that ubiquitinated myosin tends to stay in the cytosol rather than being incorporated into the thick filaments.

The myosin replacement rates differed between slow and fast myosins, i.e., eGFP-Myh7 showed the slowest myosin replacement speed (5% Rt 1.23 h ± 0.22 h) among three myosin isoforms (0.74 ± 0.10 h in eGFP-Myh1, and 1.00 h ± 0.11 h in eGFP-Myh3) and replacement speed is statistically different between Myh1 and Myh7 (Figures 2 and 3). Because the intracellular environment was identical in myotubes expressing eGFP-Myh7, eGFP-Myh1, or eGFP-Myh3, these results suggest that differences in the replacement rate were caused by the intrinsic properties of the different myosin isoforms. The amino acid sequence homology of the myosin isoforms is relatively high: Myh7 and Myh1, 81.9%. However, amino acid sequence variations are found in the tail region of Myhs, which is pivotal role in myosin filament assembly. Because amino acid composition determines the myosin axial arrangement (Atkinson & Stewart, 1992; Sohn et al., 1997), differences in the composition of the tail among myosin isoforms may change the assembly properties of myosin.

As the UPS was proposed to regulate the myosin replacement rate, it is possible that the different isoforms of myosin are differentially regulated by the UPS. The Murf family (Murf1, Murf2, and Murf3) of muscle-specific ubiquitin ligases is myosin-associated protein (Cohen et al., 2009; Fielitz et al., 2007; Pizon et al., 2002). Murfs work cooperatively, and double knockout of Murf1 and Murf3 or Murf2 and Murf3 in mice causes myosin aggregation and myopathy (Fielitz et al., 2007; Lodka et al., 2016). However, Murf expression is muscle type-specific in vivo: Murf1 is predominantly expressed in slow type myofibers, Murf2 is expressed in fast type myofibers, and Murf3 is expressed ubiquitously (Moriscot et al., 2010; Perera et al., 2012). Murfs may preferentially recognize specific myosin isoforms, which may affect the myosin replacement rate, similar to the effect of Ozz on decreasing the Myh3 replacement rate.

We propose a model of myosin replacement in the presence of Ozz overexpression (Figure 6). Overexpression of Ozz increases Myh3 ubiquitination and probably degradation, which decreases the eGFP-Myh3 replacement rate. In the differentiation stage and during muscle remodeling, Myh in the thick filaments shifts from the embryonic to the adult isoform (Schiaffino et al., 2015). The up-regulation of Ozz during muscle differentiation (Nastasi et al., 2004) results in the selective degradation of ubiquitinated Myh3, which promotes an isoform shift from embryonic myosin to neonatal/adult myosins (Campos et al., 2010). Therefore, Ozz may regulate the myosin replacement rate by catalyzing the modification of Myh3 to ensure an efficient myosin isoform shift in the thick filaments.

ACKNOWLEDGMENTS
We are grateful for the valuable technical support provided by Ms. Miho Ichimura (National Institute of Livestock and Grass Sciences, NARO).

CONFLICT OF INTEREST
The authors have no conflicts of interest to declare.

AUTHOR CONTRIBUTIONS
E.I., K.O., T.S., K.K., and T.N. designed the research; E.I. and K.O. performed the experiments; E.I., K.O., and S.M. analyzed data; E.I., K.O., and T.N. wrote the manuscript.
REFERENCES

Atkinson, S. J., & Stewart, M. (1992). Molecular interactions in myosin assembly of the 28-residue charge repeat in the rod. *Journal of Molecular Biology*, 226(1), 7–13. https://doi.org/10.1016/0022-2836(92)90118-4

Bodine, S. C., Latres, E., Baumhueter, S., Lai, V. K. M., Nunez, L., Clarke, B. A., Poueymirou, W. T., Panaro, F. J., Na, E., Dharmarajan, K., Pan, Z. Q., Valenzuela, D. M., Dechiara, T. M., Stitt, T. N., Yancopoulos, G. D., & Glass, D. J. (2001). Identification of ubiquitin ligases required for skeletal muscle atrophy. *Science* (80-), 294(5547), 1704–1708. https://doi.org/10.1126/science.1065874

Campos, Y., Qiu, X., Zanotelli, E., Moshiachi, S., Vergani, N., Bongiovanni, A., John Harris, A., & D’Azzo, A. (2010). Ozz-E3 ubiquitin ligase targets sarcomeric embryonic myosin heavy chain during muscle development. *PloS ONE*, 5(3), 1–14. https://doi.org/10.1371/journal.pone.0009866

Clark, K. A., McElhinny, A. S., Beckerle, M. C., & Gregorio, C. C. (2002). Striated muscle cytoarchitecture: An intricate web of form and function. *Annual Review of Cell and Developmental Biology*, 18, 637–706.

Cohen, S., Brault, J. J., Gygi, S. P., Glass, D. J., Valenzuela, D. M., Gartner, C., Latres, E., & Goldberg, A. L. (2009). During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitlylation. *Journal of Cell Biology*, 185(6), 1083–1095. https://doi.org/10.1083/jcb.200901052

Craig, R., & Woodhead, J. L. (2006). Structure and function of myosin filaments. *Current Opinion in Structural Biology*, 16(2), 204–212. https://doi.org/10.1016/j.sbi.2006.03.006

Dao, T. P., Kolaitis, R. M., Kim, H. J., O’Donovan, K., Martynek, B., Colicina, E., Huhnly, H., Taylor, J. P., & Castañeda, C. A. (2018). Ubiquitin modulates liquid-liquid phase separation of UBQLN2 via disruption of multivalent interactions. *Molecular Cell*, 69(6), 965–978.e6. https://doi.org/10.1016/j.molcel.2018.02.004

Davis, J. S. (1988). Assembly processes in vertebrate skeletal thick filament formation. *Annual Review of Biophysics and Biophysical Chemistry*, 17(1), 217–239. https://doi.org/10.1146/annurev.bb.17.060188.001245

Fiefitz, J., Kim, M. S., Shelton, J. M., Latif, S., Spencer, J. A., Glass, D. J., Richardson, J. A., Basal-Duby, R., & Olson, E. N. (2007). Myosin accumulation and striated muscle myopathy result from the loss of muscle RING finger 1 and 3. *Journal of Clinical Investigation*, 117(9), 2486–2495. https://doi.org/10.1172/JCI12827

Henderson, C. A., Gomez, C. G., Novak, S. M., Mi-Mi, L., & Gregorio, C. C. (2018). Overview of the muscle cytoskeleton. *Compr Physiol*, 7, 891–944.

Huang, Q., & Zhang, X. (2020). Emerging roles and research tools of atypical ubiquitination. *Proteomics*, 20(9), 1900100. https://doi.org/10.1002/pmic.201900100

Kile, B. T., Schulman, B. A., Alexander, W. S., Nicola, N. A., Martin, H. M. E., Hilton, D. J., Kile, B. T., Alexander, W. S., Nicola, N. A., Martin, H. M. E., & Hilton, D. J. (2002). The SOCS box: a tale of destruction and degradation. *TRENS Biochemical Sciences*, 27, 235–241.

Kontrogianni-Kontstantopoulos, A., Ackermann, M. A., Bowman, A. L., Yap, S. V., & Bloch, R. J. (2009). Muscle giants: Molecular scaffolds in sarcromerogenesis. *Physiological Reviews*, 89, 1217–1267.

Koyama, S., Hata, S., Witt, C. C., Ono, Y., Lerche, S., Ojima, K., Chiba, T., Doi, N., Kitamura, F., Tanaka, K., Abe, K., Witt, S. H., Rybin, V., Gasch, A., Franz, T., Labeit, S., & Sorimachi, H. (2008). Muscle RING-Finger Protein-1 (MuRF1) as a connector of muscle energy metabolism and protein synthesis. *Journal of Molecular Biology*, 376(5), 1224–1236. https://doi.org/10.1016/j.jmb.2007.11.049

Labeit, S., & Titins, K. B. (1995). Giant proteins in charge of muscle ultrastructure and elasticity. *Science* (80-), 270, 293–296.

Lagirand-cantaloube, J., Offner, N., Csibi, A., Leibovitch, M. P., Batonnnet-pichon, S., Tintignac, L. A., Segura, C. T., & Leibovitch, S. A. (2008). The initiation factor eIF3-f is a major target for Atrogenin1 / MAFbx in skeletal muscle atrophy. *The EMBO Journal*, 27(8), 1266–1276. https://doi.org/10.1038/embob.2008.52

Lecker, S. H., Goldberg, A. L., & Mitch, W. E. (2006). Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. *Journal of the American Society of Nephrology*, 17(7), 1807–1819. https://doi.org/10.1681ASN.2006010083

Lodka, D., Pahuja, A., Geers-Knorr, C., Scheibe, R. J., Nowak, M., Hamati, J., Köhncke, C., Purfürst, B., Kanashova, T., Schmidt, S., Glass, D. J., Morano, I., Heuser, A., Kraft, T., Bassel-Duby, R., Olson, E. N., Dittmar, G., Sommer, T., & Fielitz, J. (2016). Muscle RING-finger 2 and 3 maintain striated-muscle structure and function. *Journal of CACHEXIA, Sarcopenia and Muscle*, 7(2), 165–180. https://doi.org/10.1002/jcm.12057

Lokiredy, S., McFarlane, C., Ge, X., Zhang, H., Sze, S. K., Sharma, M., & Kambadur, R. (2011). Myostatin induces degradation of sarcomeric proteins through a Smad3 signaling mechanism during skeletal muscle wasting. *Molecular Endocrinology*, 25, 1936–1949.

Lokiredy, S., Wijesoma, I. W., Sze, S. K., McFarlane, C., Kambadur, R., & Sharma, M. (2012). Identification of atrogen-1-targeted proteins during the myostatin-induced skeletal muscle wasting. *American Journal of Physiology-Cell Physiology*, 305(3), C512–C529. https://doi.org/10.1152/ajpcell.00402.2011

Moriscot, A. S., Baptista, I. L., Bogomolovas, J., Witt, C., Hirner, S., Granzier, H., & Labeit, S. (2010). MuRF1 is a muscle fiber-type II associated factor and together with MuRF2 regulates type-II fiber trophicity and maintenance. *Journal of Structural Biological*, 170(2), 344–353. https://doi.org/10.1016/j.jsb.2010.02.001

Nastasi, T., Bongiovanni, A., Campos, Y., Mann, L., Toy, J. N., Bostrom, J., Rottier, R., Hahn, C., Conaway, J. W., Harris, A. J., & d’Azzo, A. (2004). Ozz-E3, a muscle-specific ubiquitin ligase, regulates β-catenin degradation during myogenesis. *Developmental Cell*, 6(2), 269–282. https://doi.org/10.1016/S1534-5807(04)00020-6

Nury, D., Doucet, C., & Coux, O. (2007). Roles and potential therapeutic targets of the ubiquitin proteasome system in muscle wasting. *BMC Biochemistry*, 8(Suppl 1), 1–10. https://doi.org/10.1186/1471-2091-8-S1-S7
Placzek, J., & Boyce, D. O. (1997). Molecular structure of the sarcomeric M band: Mapping of titin and myosin binding domains in myomesin and the identification of a potential regulatory phosphorylation site in myomesin. The EMBO Journal, 16, 211–220.

Ojima, K., Ichimura, E., Yasukawa, Y., Oz, M., Muroya, S., Suzuki, T., Wakamatsu, J. I., & Nishimura, T. (2015). Dynamics of myosin replacement in skeletal muscle cells. American Journal of Physiology-Cell Physiology, 309(10), C669–C679. https://doi.org/10.1152/ajpcell.00170.2015

Passmore, L. A., & Barford, D. (2004). Getting into position: the catalytic mechanisms of protein ubiquitylation. Biochemical Journal, 352, 513–525.

Perera, S., Mankoo, B., & Gautel, M. (2012). Developmental regulation of MURF E3 ubiquitin ligases in skeletal muscle. Journal of Muscle Research and Cell Motility, 33(2), 107–122. https://doi.org/10.1007/s10974-012-9288-7

Pizon, V., Iakovenko, A., van der Ven, P. F. M., Kelly, R., Fatu, C., Fürst, D. O., Karsenti, E., & Gautel, M. (2002). Transient association of titin and myosin with microtubules in nascent myofibrils directed by the MURF2 RING-finger protein. Journal of Cell Science, 115(23), 4469–4482. https://doi.org/10.1242/jcs.00131

Placzek, J., & Boyce, D. (2016). Orthopaedic Physical Therapy Secrets (3rd ed.). Elsevier. https://www.elsevier.com/books/orthopaedic-physical-therapy-secrets-e-book/placzek/978-0-323-28683-1.

Prill, K., & Dawson, J. F. (2020). Assembly and maintenance of sarcomere thin filaments and associated diseases. International Journal of Molecular Sciences, 21(2), 1–20. https://doi.org/10.3390/ijms21020542

Resnicow, D. I., Deacon, J. C., Warrick, H. M., Spudich, J. A., & Leinwand, L. A. (2010). Functional diversity among a family of human skeletal muscle myosin motors. Proceedings of the National Academy of Sciences of the United States of America, 107(3), 1053–1058. https://doi.org/10.1073/pnas.0913527107

Rubinstein, N., Chi, J., & Holtzer, H. (1976). Coordinated synthesis and degradation of actin and myosin in a variety of myogenic and non-myogenic cells. Experimental Cell Research, 97(2), 387–393. https://doi.org/10.1016/0014-4827(76)90630-3

Schiaffino, S., Rossi, A. C., Smerdu, V., Leinwand, L. A., & Reggiani, C. (2015). Developmental myosins: Expression patterns and functional significance. Skeletal Muscle, 5, 1–14.

Sharkey, L. M., Safren, N., Pithadia, A. S., Gerson, J. E., Dulchavsky, M., Fischer, S., Patel, R., Lantis, G., Ashraf, N., Kim, J. H., Meliki, A., Minakawa, E. N., Barnada, S. J., Ivanova, M. I., & Paulson, H. L. (2018). Mutant UBQLN2 promotes toxicity by modulating intrinsic self-assembly. Proceedings of the National Academy of Sciences of the United States of America, 115(44), E10495–E10504. https://doi.org/10.1073/pnas.1810522115

Sohn, R. L., Vikstrom, K. L., Strauss, M., Cohen, C., Szent-Gyogyi, A. G., & Leinwand, L. A. (1997). A 29 residue region of the sarcomeric myosin rod is necessary for filament formation. Journal of Molecular Biology, 266, 317–330.

Solomon, V., & Goldberg, A. L. (1996). Importance of the ATP-ubiquitin-proteasome pathway in the degradation of soluble and myofibrillar proteins in rabbit muscle extracts. Journal of Biological Chemistry, 271(43), 26690–26697. https://doi.org/10.1074/jbc.271.43.26690

Tintignac, L. A., Lagirand, J., Batonneau, S., Sirri, V., Leibovitch, M. P., & Leibovitch, S. A. (2005). Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase. Journal of Biological Chemistry, 280(4), 2847–2856. https://doi.org/10.1074/jbc.M411346200

Walklate, J., Ujfalusi, Z., & Geeves, M. A. (2016). Myosin isoforms and the mechanochemical cross-bridge cycle. Journal of Experimental Biology, 219(2), 168–174. https://doi.org/10.1242/jeb.124594

Zak, R., Martin, A. F., Prior, G., & Rabinowitz, M. (1977). Comparison of turnover of several myofibrillar proteins and critical evaluation of double isotope method. Journal of Biological Chemistry, 252(10), 3430–3435. https://doi.org/10.1016/S0021-9258(17)40409-1

How to cite this article: Ichimura, E., Ojima, K., Muroya, S., Suzuki, T., Kobayashi, K., & Nishimura, T. (2021). The ubiquitin ligase Ozz decreases the replacement rate of embryonic myosin in myofibrils. Physiological Reports, 9, e15003. https://doi.org/10.14814/phy2.15003